Exelon (EXC)

Total Liabilities

$90.81B

Quarterly · Period ending: · USD

EXC logo

EXC Total Liabilities

Latest reported$90.81B
EXC Quarterly Total Liabilities ($10.25B → $90.81B)
High-resolution chart · PNG

EXC total liabilities history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Exelon Total Liabilities — Quarterly (USD)
Period endingTotal Liabilities (USD)
90,807,000,000
88,230,000,000
87,772,000,000
85,426,000,000
83,527,000,000
81,877,000,000
80,863,000,000
79,448,000,000
78,961,000,000
77,150,000,000
76,101,000,000
73,789,000,000
73,001,000,000
71,859,000,000
70,605,000,000
68,873,000,000
68,639,000,000
69,207,000,000
98,218,000,000
98,362,000,000
94,896,000,000
95,687,000,000
94,449,000,000
92,664,000,000
91,442,000,000
90,061,000,000
90,404,000,000
88,386,000,000
87,689,000,000
87,889,000,000
86,587,000,000
86,097,000,000
84,410,000,000
84,453,000,000
84,583,000,000
88,156,000,000
87,814,000,000
88,777,000,000
87,292,000,000
87,075,000,000
85,480,000,000
84,556,000,000
68,090,000,000
67,839,000,000
67,144,000,000
62,753,000,000
62,283,000,000
60,214,000,000
59,427,000,000
56,690,000,000
56,984,000,000
57,594,000,000
56,832,000,000
56,917,000,000
56,831,000,000
56,250,000,000
55,112,000,000
55,526,000,000
40,607,000,000
39,797,000,000
37,871,000,000
37,442,000,000
38,677,000,000
36,993,000,000
35,987,000,000
37,290,000,000
36,540,000,000
37,012,000,000
36,826,000,000
36,764,000,000
36,499,000,000
33,627,000,000
36,913,000,000
36,015,000,000
35,224,000,000
35,298,000,000
34,134,000,000
34,595,000,000
34,312,000,000
31,946,000,000
32,555,000,000
33,109,000,000
33,671,000,000
32,994,000,000
32,042,000,000
32,694,000,000
33,193,000,000
32,460,000,000
33,026,000,000
34,803,000,000
33,433,000,000
30,816,000,000
31,831,000,000
31,819,000,000
30,050,000,000
26,650,000,000
27,275,000,000
26,852,000,000
26,611,000,000
27,848,000,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.